67% vs 32%: The PTSD Result the FDA Couldn't Ignore #shorts

Phase 3 trials of MDMA-assisted therapy showed 67% of treatment-resistant PTSD patients no longer met diagnostic criteria — versus 32% on placebo with therapy alone. More than four times the effect size of any approved PTSD medication in history. So why did the FDA say no?

▶ Full episode on what happened and what's next: https://www.youtube.com/watch?v=kRYsE84t-10

The science · The medicine · The future
🔔 Subscribe — new videos Tuesdays & Fridays.

⚠️ Educational only. Not medical advice.

#psychedelics #Shorts #MDMA #PTSD #FDA #clinicaltrials #phase3 #MAPS #effectsize #mentalhealth

Видео 67% vs 32%: The PTSD Result the FDA Couldn't Ignore #shorts канала Psychedelics University